Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab

Gut microbiota is involved in immune modulation and immune checkpoint inhibitors (ICIs) efficacy. Single‐arm phase II CAVE‐mCRC and CAVE‐LUNG clinical trials investigated cetuximab + avelumab combination in RAS wild‐type (WT) metastatic colorectal cancer (mCRC) and chemo‐refractory nonsmall cell lun...

Descripción completa

Detalles Bibliográficos
Autores principales: Martini, Giulia, Ciardiello, Davide, Dallio, Marcello, Famiglietti, Vincenzo, Esposito, Lucia, Corte, Carminia Maria Della, Napolitano, Stefania, Fasano, Morena, Gravina, Antonietta Gerarda, Romano, Marco, Loguercio, Carmelina, Federico, Alessandro, Maiello, Evaristo, Tuccillo, Concetta, Morgillo, Floriana, Troiani, Teresa, Di Maio, Massimo, Martinelli, Erika, Ciardiello, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Tumor Markers and Signatures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321613/
https://www.ncbi.nlm.nih.gov/pubmed/35429341
http://dx.doi.org/10.1002/ijc.34033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321613/
https://www.ncbi.nlm.nih.gov/pubmed/35429341
http://dx.doi.org/10.1002/ijc.34033

Ejemplares similares